Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Copeland who wrote (506)	11/16/1999 7:31:00 PM
From: shadowman	Respond to of 645

I've been watching this company for a couple of years based on the promise of Flumist....the study (test) in Texas etc. I have yet to buy their stock. From what I've observed they may have a promising product but management seems to leave something to be desired. Not impressed with the way they've handled things the past year or so. Still watching.

To: Copeland who wrote (506)	11/17/1999 10:55:00 AM
From: Edscharp	Read Replies (1) \| Respond to of 645

Copeland, I phrased my response the way I did because of the following statement from the recent news releases. "The company said it is investigating some of the tests and will determine the need for any additional validation work on the test or the manufacturing process. Aviron said that Medeva Pharma Ltd., a unit of Medeva Plc (NYSE: MDV) which manufactures components of the vaccine, has notified Aviron of facilities compliance issues at its facility near Liverpool." As is usual with releases of this kind one can make mulitple interpretations or read too deeply into the phraseology, however, I took the above to simply mean that Aviron would proceed cautiously and investigate any additional compliance issues that might prevent final approval. One could read deeper into the statement and hypothesize that Medeva (or Aviron) has discovered a potential problem in the area of vaccine manufacturing, but I would hope if this was the concern that Aviron would be more plain and honest with it's shareholders. But, I appreciate that this isn't always the case. I will admit, it's not clear whether Aviron is simply being thorough or if an "avoidable problem" has popped up.